**Core Concept**
Rosiglitazone is a thiazolidinedione (TZD) that acts as an insulin sensitizer. It increases insulin sensitivity in peripheral tissues, thereby reducing glucose levels in the blood. Unlike other antidiabetic agents, rosiglitazone does not directly stimulate insulin release from the pancreatic beta cells.

**Why the Correct Answer is Right**
Rosiglitazone works by activating the peroxisome proliferator-activated receptor gamma (PPAR-γ) in the nucleus of adipose tissue and skeletal muscle cells. This activation leads to increased expression of genes involved in glucose uptake and utilization, such as glucose transporter type 4 (GLUT4). As a result, there is an increase in insulin sensitivity, but not an increase in insulin release. In fact, rosiglitazone can even decrease insulin secretion by reducing the expression of insulin gene in pancreatic beta cells.

**Why Each Wrong Option is Incorrect**
**Option B:** Nateglinide is a meglitinide that stimulates insulin release by closing potassium channels in the pancreatic beta cells, leading to depolarization and opening of calcium channels, which in turn triggers insulin release.
**Option C:** Glipizide is a sulfonylurea that also stimulates insulin release by binding to sulfonylurea receptors on the pancreatic beta cells, leading to closure of potassium channels and depolarization.
**Option D:** Exenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist that stimulates insulin release by increasing glucose-dependent insulin secretion and suppressing glucagon release.

**Clinical Pearl / High-Yield Fact**
When choosing an antidiabetic agent, it's essential to consider the mechanism of action and potential side effects. For example, sulfonylureas like glipizide can cause hypoglycemia, while thiazolidinediones like rosiglitazone can increase the risk of heart failure.

**✓ Correct Answer: A. Rosiglitazone**